Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study

Clinical Therapeutics

Volumn 31, Issue 5, 2009, Pages 1069-1081

  Weycker, Derek ^a   Malin, Jennifer ^b   Kim, John ^b   Barron, Rich ^b   Edelsberg, John ^a   Kartashov, Alex ^a   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

Author keywords

febrile neutropenia; filgrastim; outcomes; pegfilgrastim

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; COHORT ANALYSIS; HOSPITALIZATION; HUMAN; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SOLID TUMOR; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FILGRASTIM; HOSPITALIZATION; HUMANS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; ODDS RATIO; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 66949174442     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.05.019     Document Type: Article

References (25)

1. Caggiano V., Weiss R.V., Rickert T.S., and Linde-Zwirble W.T. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103 (2005) 1916-1924
2. Smith T.J., Khatcheressian J., and Lyman G.H. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 24 (2006) 3187-3205
3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections (2008). http://www.nccn.org/professionals/physician_gls/PDP/infections.pdf Accessed February 5, 2009
4. Neupogen (filgrastim) [package insert]. http://www.neupogen.com/pi.html Accessed November 27, 2007
5. Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 325 (1991) 164-170
6. Neulasta (pegfilgrastim) [package insert]. http://www.amgen.com/pdfs/misc/neulasta_pi.pdf Accessed November 27, 2007
7. Yang B.B., Kido A., and Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 27 (2007) 1387-1393
8. Green M.D., Koelbl H., Baselga J., et al., International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14 (2003) 29-35
9. Holmes F.A., Jones S.E., O'Shaughnessy J., et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. Ann Oncol. 13 (2002) 903-909
10. Grigg A., Solal-Celigny P., Hoskin P., et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 44 (2003) 1503-1508
11. Vose J.M., Crump M., Lazarus H., et al. Randomized, multi-center, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 21 (2003) 514-519
12. Holmes F.A., O'Shaughnessy J.A., Vukelja S., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20 (2002) 727-731
13. Siena S., Piccart M.J., Holmes F.A., et al. A combined analysis of two pivotal randomized trials of a single dose of pegfil-grastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 10 (2003) 715-724
14. Pinto L., Liu Z., Doan Q., et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutrope-nia and bone pain: A meta-analysis of randomized controlled trials. Curr Med Res Opin. 23 (2007) 2283-2295
15. Almenar D., Mayans J., Bueno J.M., et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: Patterns of use and neutropenia-related outcomes in cancer patients in Spain-results of the LEARN study. Eur J Cancer Care (Engl). 18 (2009) 280-286
16. Weycker D., Hackett J., Edelsberg J.S., et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?. Ann Pharmacother 40 (2006) 402-407
17. Morrison V.A., Wong M., Hershman D., et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 13 (2007) 337-348
18. Ip E.J., Lee-Ma A., Troxell L.S., and Chan J. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxo-rubicin, and cyclophosphamide. Am J Health Syst Pharm. 65 (2008) 1552-1555
19. von Minckwitz G., Kummel S., du Bois A., et al., German Breast Group. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19 (2008) 292-298
20. Adamson D.M., Chang S., and Hansen L.G. Health research data for the real world: The MarketScan databases (2006), Thomson Medstat, Ann Arbor, Mich
21. Health Insurance Portability and Accountability Act of 1996, 42 USC §1320-d2.
22. US Dept of Health & Human Services. Public Welfare-Protection of Human Subjects, 45 CFR 46. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm Accessed February 20, 2008
23. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Myeloid growth factors (2008). http://www.nccn.org/professionals/physician_gls/PDP/myeloid_growth.pdf Accessed February 20, 2008
24. Weycker D., Malin J., Edelsberg J., et al. Cost of neutropenic complications of chemotherapy. Ann Oncol. 19 (2008) 454-460
25. Romano P.S., Roos L.L., and Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol. 46 (1993) 1075-1079